Shares of Impel NeuroPharma Inc. (NASDAQ:IMPL) traded at a new 52-week high today of $34.78. Approximately 605,000 shares have changed hands today, as compared to an average 30-day volume of 217,000 shares.
In the past 52 weeks, Impel NeuroPharma Inc. share prices are bracketed by a low of $6.90 and a high of $34.78 and is now at $28.20, 308% above that low price.
Impel NeuroPharma Inc is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Its pipeline of proprietary product candidates includes INP107 for the treatment of OFF episodes in Parkinson’s Disease.
Based on a current price of $28.20, Impel NeuroPharma Inc. is currently 52.0% above its average consensus analyst price target of $13.53.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer